Life Briefing: Medicare Chief Discusses TrumpRx's Narrow Focus Strategic angle: Today's biotech news includes insights from the Medicare director on the scope of TrumpRx and the FDA's approval of high-dose Wegovy. editorial-staff Mar 20
Life Briefing: STAT+: Up and down the ladder: The latest comings and goings Strategic angle: From new hires to departures and promotions, here are the latest comings and goings in the pharmaceutical industry. editorial-staff Mar 20
Life Briefing: A conversation with the ‘godfather’ of biotech Strategic angle: This week on 'The Readout LOUD,' a conversation with biotech 'godfather' Stelios Papadapolous live from #STATBreakthrough. editorial-staff Mar 20
Life Briefing: All the highlights from STAT’s Breakthrough Summit East Strategic angle: In today's Morning Rounds newsletter, the highlights from #STATBreakthrough, a ruling against Kennedy’s gender-affirming care declaration, and more. editorial-staff Mar 20
Life Briefing: Pharmalittle: Insights on TrumpRx and Wegovy Strategic angle: Exploring expectations around TrumpRx and a new high-dose version of Wegovy. editorial-staff Mar 20
Life Briefing: U.K. to Reassess Cost-Effectiveness of Alzheimer's Drugs Strategic angle: Following successful appeals from drugmakers, the U.K. is reviewing the cost-effectiveness of two new Alzheimer's treatments. editorial-staff Mar 20
Life Briefing: A family’s giving to the Broad Institute’s research tops $1 billion Strategic angle: The Broad Institute of MIT and Harvard is poised to receive a massive injection of cash to fund research in the understanding and treatment of bipolar disorder and schizophrenia. editorial-staff Mar 20
Life Briefing: Congress must fix the No Surprises Act before it bankrupts patients and employers Strategic angle: James Gelfand and Patricia Kelmar argue for urgent reforms to the No Surprises Act to protect patients and employers from financial ruin. editorial-staff Mar 20
Life Briefing: Tobacco could get a boost from the farm bill. How does that square with MAHA? Strategic angle: The farm bill shows politicians catering to the agriculture industry risk losing the support of MAHA while running afoul of public health goals. editorial-staff Mar 20
Life Briefing: Political influence ‘a serious problem’ for FDA under Trump, former commissioner says Strategic angle: Robert Califf highlights the shift towards political decision-making in the FDA during the Trump administration. editorial-staff Mar 20
Life Briefing: Judge to Vacate Kennedy's Declaration on Gender-Affirming Care Strategic angle: A U.S. district judge is set to rule against a declaration by Kennedy regarding the medical standards of gender-affirming care for young trans individuals. editorial-staff Mar 20
Life Briefing: Drug development is booming in China. Should the U.S. view it as a threat or an opportunity? Strategic angle: If the U.S. wants to hold on to its title as the world's top biotech innovator, it might want to take a page out of China's book. editorial-staff Mar 19
Life Briefing: Independent autism committee kicks off efforts to counter RFK Jr., influence Congress Strategic angle: A group of autism scientists kicked off efforts Thursday to influence Congress, and the research agendas of private organizations. editorial-staff Mar 19
Life Briefing: Trump’s Medicare Director Seeks to Rein in Expectations for TrumpRx Strategic angle: The Trump administration is counting on its drug pricing efforts to help with the midterm elections. editorial-staff Mar 19
Life Briefing: HHS Public Health Policy Actions Under the Trump Administration 2025-2026 Strategic angle: A comprehensive timeline of public health policy actions by the Department of Health and Human Services (HHS) under the Trump administration from 2025-2026. editorial-staff Mar 19
Life Briefing: Medicaid Postpartum Coverage Extension Tracker Strategic angle: This page tracks recent state actions to extend Medicaid postpartum coverage. editorial-staff Mar 19
Life Briefing: What to Know About Medicare Coverage of Telehealth Strategic angle: Congress has repeatedly extended several pandemic-era flexibilities around Medicare coverage of telehealth, but most remain temporary. editorial-staff Mar 19
Life Novo Nordisk’s high-dose Wegovy approved in the U.S. A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval. editorial-staff Mar 19
Life Senate Democrats Lay Out Plans to Overhaul Health Insurance After Setbacks Under Trump Democrats are sharpening their health care message as the midterms loom. editorial-staff Mar 19
Life Briefing: Eli Lilly’s ‘triple-G’ shows potency, raises concerns Strategic angle: Eli Lilly's 'triple-G' drug shows potency, In-vivo CAR-T inches toward clinical reality, and more in today's Readout newsletter. editorial-staff Mar 19